Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 14/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256577 | 0.81 | PDPK1 (0.47) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL24009146 | 0.80 | PDPK1 (0.47) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL12074900 | 0.79 | RET (0.48) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL21358423 | 0.78 | EGFR (0.49) | CSF1R | |
| SCHEMBL21358444 | 0.77 | PDPK1 (0.47) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL23634745 | 0.75 | POLB (0.42) | PDPK1DAPK3PRKD3FLT1RPS6KA3 | |
| SCHEMBL4743752 | 0.75 | SRC (0.62) | — | |
| SCHEMBL5498230 | 0.73 | SRC (0.59) | — | |
| Amiquinsin SCHEMBL242841 | 0.73 | EHMT2 (0.63) | — | |
| SCHEMBL4986639 | 0.73 | PDPK1 (0.74) | PDPK1DAPK3PRKD3FLT1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2588457-A1 | PYRAZOLO-QUINOLINES | Merck Patent GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | PDPK1 67/4885DAPK3 283/4885PRKD3 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.